Engineers at the University of California San Diego have developed neutrophil “nanosponges” that can safely absorb and neutralize a variety of proteins that play a role in the progression of rheumatoid arthritis. Injections of these nanosponges effectively treated severe rheumatoid arthritis in two mouse models. Administering the nanosponges early on also prevented the disease from developing.
The work is published Sept. 3 in Nature Nanotechnology.
“Nanosponges are a new paradigm of treatment to block pathological molecules from triggering disease in the body,” said senior author Liangfang Zhang, a nanoengineering professor at the UC San Diego Jacobs School of Engineering. “Rather than creating treatments to block a few specific types of pathological molecules, we are developing a platform that can block a broad spectrum of them, and this way we can treat and prevent disease more effectively and efficiently.”
This work is one of the latest examples of therapeutic nanosponges developed by Zhang’s lab. Zhang, who is also affiliated with the Institute of Engineering in Medicine and Moores Cancer Center at UC San Diego, and his team previously developed red blood cell nanosponges to combat and prevent MRSA infections and macrophage nanosponges to treat and manage sepsis.
The new nanosponges are nanoparticles of biodegradable polymer coated with the cell membranes of neutrophils, a type of white blood cell.
Neutrophils are among the immune system’s first responders against invading pathogens. They are also known to play a role in the development of rheumatoid arthritis, a chronic autoimmune disease that causes painful inflammation in the joints and can ultimately lead to damage of cartilage and bone tissue.
When rheumatoid arthritis develops, cells in the joints produce inflammatory proteins called cytokines. Release of cytokines signals neutrophils to enter the joints. Once there, cytokines bind to receptors on the neutrophil surfaces, activating them to release more cytokines, which in turn draws more neutrophils to the joints and so on.
The nanosponges essentially nip this inflammatory cascade in the bud. By acting as tiny neutrophil decoys, they intercept cytokines and stop them from signaling even more neutrophils to the joints, reducing inflammation and joint damage.
These nanosponges offer a promising alternative to current treatments for rheumatoid arthritis. Some monoclonal antibody drugs, for example, have helped patients manage symptoms of the disease, but they work by neutralizing only specific types of cytokines. This is not sufficient to treat the disease, said Zhang, because there are so many different types of cytokines and pathological molecules involved.
“Neutralizing just one or two types might not be as effective. So our approach is to take neutrophil cell membranes, which naturally have receptors to bind all these different types of cytokines, and use them to manage an entire population of inflammatory molecules,” said Zhang.
“This strategy removes the need to identify specific cytokines or inflammatory signals in the process. Using entire neutrophil cell membranes, we’re cutting off all these inflammatory signals at once,” said first author Qiangzhe Zhang, a Ph.D. student in Professor Liangfang Zhang’s research group at UC San Diego.
To make the neutrophil nanosponges, the researchers first developed a method to separate neutrophils from whole blood. They then processed the cells in a solution that causes them to swell and burst, leaving the membranes behind. The membranes were then broken up into much smaller pieces. Mixing them with ball-shaped nanoparticles made of biodegradable polymer fused the neutrophil cell membranes onto the nanoparticle surfaces.
“One of the major challenges of this work was streamlining this entire process, from isolating neutrophils from blood to removing the membranes, and making this process repeatable. We spent a lot of time figuring this out and eventually created a consistent neutrophil nanosponge production line,” said Qiangzhe Zhang.
In mouse models of severe rheumatoid arthritis, injecting nanosponges in inflamed joints led to reduced swelling and protected cartilage from further damage. The nanosponges performed just as well as treatments in which mice were administered a high dose of monoclonal antibodies.
The nanosponges also worked as a preventive treatment when administered prior to inducing the disease in another group of mice.
Professor Liangfang Zhang cautions that the nanosponge treatment does not eliminate the disease. “We are basically able to manage the disease. It’s not completely gone. But swelling is greatly reduced and cartilage damage is minimized,” he said.
The team hopes to one day see their work in clinical trials.
Receive an email update when we add a new RHEUMATOID ARTHRITIS article.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Reumatoid arthritis
- Arthritis: What’s the best type of food to treat arthritis pain? on November 13, 2018 at 5:47 am
ARTHRITIS is a lifelong condition that can be painful to live with. There’s no direct cure, but symptoms can be improved by eating certain foods and taking certain supplements. This type of food has b... […]
- Does Sexism Play a Role in Rheumatoid Arthritis Care? on November 11, 2018 at 3:20 pm
Growing up, Maya Dusenbery, 32, never thought about her health, which, as a high school and college soccer star, was stellar. She also didn’t give much thought to her doctors, since she saw them prima... […]
- What It's Like to Be a Single Mom With Rheumatoid Arthritis on November 10, 2018 at 10:09 pm
What is it like when constant unrelenting fatigue and pain consume your world? Making every aspect of your life a consistent struggle to maintain some quality of life requiring hours of seemingly self... […]
- Generic arthritis drug comes up short against inflammation in heart disease on November 10, 2018 at 1:51 pm
Giving a generic anti-inflammatory drug widely used to treat rheumatoid arthritis to people who previously had a heart attack or stroke worked no better than placebo in preventing another cardiovascul... […]
- Rheumatoid arthritis (RA): Prognosis on November 9, 2018 at 7:14 am
Healthline Media, Inc. would like to process and share personal data (e.g., mobile ad id) and data about your use of our site (e.g., content interests) with our third party partners (see a current lis... […]
- Rheumatoid Arthritis Treatment Market 10-Year Market Forecast and Trends Analysis Research Report on November 9, 2018 at 4:24 am
Future Market Insights has announced the addition of the “Rheumatoid Arthritis Treatment Market: Global Industry Analysis and Opportunity Assessment 2017-2027" report to their offering Rheumatoid arth... […]
- Medical News Today: What to know about rheumatoid arthritis and weight loss on November 8, 2018 at 5:00 am
While being overweight or obese can increase the risk of developing rheumatoid arthritis (RA), some people with the condition lose weight. In this article, learn about the relationship between RA ... […]
- Medical News Today: What's the difference between rheumatoid arthritis and osteoarthritis? on November 8, 2018 at 3:00 am
Rheumatoid arthritis (RA) and osteoarthritis (OA) are two conditions that cause pain and stiffness in the joints. They have different causes and treatments. Learn about the differences between RA ... […]
- Johnson & Johnson drops OSE’s rheumatoid arthritis drug on November 2, 2018 at 6:08 am
Johnson & Johnson has dumped OSE Immunotherapeutics’ autoimmune candidate FR104. J&J picked up the rights to the CD28 antagonist for €10 million ($11 million) upfront in 2016 but clinical progress sta... […]
via Bing News